Chairman of the Customs Committee of Uzbekistan Akmalxo'ja Mavlonov, during a meeting with pharmaceutical industry representatives, emphasized the need to regulate medicine imports, strengthen quality control, and jointly resolve accumulated issues.

According to Mavlonov, the pharmaceutical sector's turnover in 2025 reached $2 billion, an 18% increase compared to 2024. Export volume amounted to $32 million.

He noted that pharmaceutical imports are only slightly behind food imports: "We are consuming food products and medicines in almost the same volume. This is a very large figure. The first thing we must do is reduce this indicator."

85% of imports (approximately $1.7 billion) consist of finished medicines. Key importers include Grand Pharm Trade, Meros Pharm, Farm Lyuks Invest, GD Pharm, Eurofarm Business, and Astor Alliance.

Mavlonov specifically highlighted the inadmissibility of importing substandard drugs: "Medicines with expired shelf life, poor quality, or adverse effects should not enter the country."

Regulation of the pharmaceutical sector is under the "personal control" of the president. Starting from 2026, medicines can only be stored in customs and free warehouses that meet GCP requirements and have proper storage conditions.

Source: www.gazeta.uz